Stay updated on Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Sign up to get notified when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.

Latest updates to the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial record is displayed in place of a 403 error page, showing study details, outcomes, eligibility information, locations, and supporting documents.SummaryDifference90%

- Check21 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH notice announces a transition in terminology, stating that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the change.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site revision displayed in the footer changed from v3.7.0 to v3.7.1 on the forbidden page.SummaryDifference0.2%

- Check63 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the expected study content and blocking access to the NCT03318939 record. This appears to be an access/configuration issue rather than a content update.SummaryDifference19%

Stay in the know with updates to Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Poziotinib in NSCLC with EGFR/HER2 Insertion Clinical Trial page.